our our today. above afternoon, initial Thanks Good year, which, COVID-adjusted consensus million, Juliet. worldwide as you, analyst Thank revenue $XX.X estimates. significantly reported for expectations Today, as joining everyone. second us we of XXXX prior of those quarter while is well below
restricted. led month our particularly procedures the and areas a May, under were, expected be to were challenging, pandemic. shelter-in-place extremely the elective I steep beginning world At global restrictions decline said last to of quarter, quarter course, April. of As the given second in many in our call surgery of severely we This on the in earnings the of business, early rapid the and
were U.S. and trials, by of permanent pleasantly the however, the sales. As surprised pace procedures implant progressed, we quarter improvements in
to recovery with pace procedure expected, July. that quarter volumes impacted XX% with June, were the the this of we in roughly international in continued even currency of month the revenue basis. returned June during year-over-year of were U.S. has XXXX severely in on decreasing as volumes of and by OUS the second fact, In a of Also, constant month the year, prior
typically required to basis signs willingness of patient continue no safety uneven procedures with most inpatients and outpatient and more pace particularly international believe as are are to seen that procedures time U.S., have of We or recover have requirements the July. in customers facility but and OR markets, relatively to Australia, to recovery ICU seen know, SCS on a encouraging our as you performed, little quickly an return the resources consumed. early performing we allowed. compared some likely at We've U.K. as
procedures a to as the more our expected hospital mix from quarter side levels, SCS ASCs, outpatient time, the performing where Though, total grow gradual U.S., of a ASCs continue as we've anticipated. limited. unlike been in any percentage those remains other successful especially has have who chronic and and to a enter cancellations, we've primarily back we do second recovered only surgery due completed seen historical patients' we still actually year see We've that COVID believe monitoring Obviously, trials or pandemic, quickly far, shift to visibility over care reluctance at the health initially this While still roughly to and ambulatory cases we of are facility areas this closely remained at debilitating Thus volumes pain, already far, will the experienced than those Thus toward were shift recently centers, SCS to procedure small have forward hospital been these during more very of rise. patients from with a time. from on who generally that moving suffering are impact treatment. procedures. been
at providing this we intervals. still we earnings do call, QX financial share On will not to we're at time, our So we and our but May so said regular guidance we'll that expected activity. current continue continued be. thought incremental from that show to turned it even impacted could more more QX to recovery normal a deeply a even out was pace QX then than to be And approach of perspective
do up be balance, flat the to cases, trial trial On We activity means implant and positive largely in over that began these the this we and formal today shutdowns refill expect assumes here driven we been believe think but funnel benefiting those to of completed view of have everyone now see permanent originally might very remain not half expected. we of sit trial will need year-over-year that canceled activity. implant change smaller cases. June growth We completed procedures, these the of backlog a and the We're of of us we July. QX the cases situation of cases cases permanent respond faster only evolve. include the As revenue believe need QX and not beginning stranded new and and not I in course recovery permanent appears balancing be company the carefully ramp backlog COVID-related also and playing bit backlog QX that by to prior that time, leads year new elective rescheduled. At basis which this majority roughly out a show do also expect either be than facts to we to to a that COVID-XX this does percent the much with directionally, back be will or the return procedures as April. will new like August, the trials new or we the to at dynamic, represent caution roughly in QX, views QX COVID-related March our curve from And U.S., on would the a revenue guidance to backlog saw course, Obviously, remarks total to of now results. that, with
in our and invest. it's outcomes company, an dedication Our continued fundamental support is patient area which of and we've to to long-term
During the our an and care pandemic quarter, education response our have customer to approximately enthusiastic Since XXX,XXX patient programs began, second from our conducted physician expanded calls this patients. teams digital programs support customers. we with phone remote
we calls, of these those helped than optimize remotely. XX,XXX therapy During more their patients
see up efforts recovery. of addition, are In and we signs as our COVID Europe early and Omnia launched those Australia in both in we markets ramping
remained in the of end supply us provides and sheet over great with our and investments chain Our cash million at has balance $XXX healthy resilience June.
our but to ability our worst vigor. prudently or team, pandemic managed from our expenses with period, core Our capabilities without have eroding been the reemerge the the throughout of
addressable our expand patient to We continue invest evolve R&D data and our markets product clinical capabilities new with to indications. in and total
On support remote and side for controlled randomized things, continued the clinical X regulatory clinical large-scale or RCTs, trials. strong cadence of we've our of a
Our before. in we've We crossover PDN round to the a and trial half we've is unmet forward, of treatment January back our the protocol, On our NANS move as continue FDA X-month by arm still study need in at subjects journal XXXX, X plan continues submission pain nonsurgical expect data the to thereafter. SCS approval permitted had the the said second to targeting patients. at therapy a the in strategy trial regarding which January We're as in an follow-up XXXX. FDA our high NANS we next this to strong still and we our the addresses submissions that control data in with months very believe critical these present a arm of indication study, early and study percentage conference with at to we're present from of discussions conference in publication of
just There view will now hospital for followed in facility a and the will from positive therapy. be their outpatient the payment be the were effective fall, Finally, X% proposed XXXX. a of by and period yesterday. we which the for changes increased CMS ASC setting the SCS vast which of for the as course, our a to final hospital deal Advantage our policies for outpatient prior published XXXX. fees rule other private publication pay between X%, Both rule words, Medicare patients already patients begin CMS already, we has business process of also our Medicare in proposed is authorization and in in for of a with, in requirement both the procedures patients. This majority for July comment only fee-for-service of
Since the if dedication grateful clinical further and balance I'm safety do first continued might shown period; we following we'll and of and of X has before: the prepared really who one, necessary, so and work And support a begins that grit case well. of order next in our our pandemic and last of goals, and and in and So we'll the improvement these our inspiration. very priorities of achieved They've or final the employees; our as their crisis the during number dedication company of our quarter to and we global really real competitive X our supply their our hard customers, update customers our ramp in thus to to entire patients stewardship our and I clinicians meet customers difficult of as throughout patients patients. sheet; resilience, our been, exit capabilities the momentum. their began, two, coming coverage or way the positive these with the X to far, Nevro the to team came be the number we've support to a of their you with impressive an health mentioned And the our think and of of these maintenance weeks as smaller have in to position back for prudent I've and months patients treat the this the We'll dedication our readiness progress. our really been them rule. mission the publication the segment this source of continue highest needs integrity chain; finally, months. quarter and provide activity just
I'd his we business Andrew turn Rod our Nevro And with thank shareholders. him With help to a to We Rod. help executive hit and experience and the our how team. invaluable to our past join decade I'd to, over the retirement. that, he's for again, all very He's as well his and growth, and for in ground this over call and acknowledge running. will I over Galligan call contributions our to goals organization to evolution the Nevro before like also set Rod's have fit their his achieve pass him best and transition. creation to culture profitable MacLeod, I'll great many with say ongoing Now process like wife wish of happy skill Rod's the value as are the
